VXRT

Vaxart (VXRT)

Vaxart Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VXRT

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/14	05 : 11	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VXRT	Vaxart Inc
2024/05/14	05 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2024/05/14	05 : 01	GlobeNewswire Inc.	Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results	NASDAQ:VXRT	Vaxart Inc
2024/05/13	20 : 10	IH Market News	U.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed Reactions	NASDAQ:VXRT	Vaxart Inc
2024/05/07	21 : 00	GlobeNewswire Inc.	Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13	NASDAQ:VXRT	Vaxart Inc
2024/04/30	21 : 00	GlobeNewswire Inc.	Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers	NASDAQ:VXRT	Vaxart Inc
2024/03/27	21 : 00	GlobeNewswire Inc.	Vaxart to Present at World Vaccine Congress Washington 2024 on April 3	NASDAQ:VXRT	Vaxart Inc
2024/03/20	21 : 00	GlobeNewswire Inc.	Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:VXRT	Vaxart Inc
2024/03/15	05 : 01	GlobeNewswire Inc.	Vaxart Provides Business Update and Reports Full Year 2023 Financial Results	NASDAQ:VXRT	Vaxart Inc
2024/03/14	20 : 41	IH Market News	U.S. Stock Futures Rise Ahead Of PPI and Retail Sales; Oil Prices Climb	NASDAQ:VXRT	Vaxart Inc
2024/03/07	22 : 00	GlobeNewswire Inc.	Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14	NASDAQ:VXRT	Vaxart Inc
2024/03/06	23 : 23	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2024/03/06	22 : 00	GlobeNewswire Inc.	Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director	NASDAQ:VXRT	Vaxart Inc
2024/03/01	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2024/02/16	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2024/02/14	07 : 16	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VXRT	Vaxart Inc
2024/02/05	22 : 00	GlobeNewswire Inc.	Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge	NASDAQ:VXRT	Vaxart Inc
2024/02/03	06 : 49	Edgar (US Regulatory)	Form 8-K/A - Current report: [Amend]	NASDAQ:VXRT	Vaxart Inc
2024/01/20	07 : 14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2024/01/20	06 : 30	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:VXRT	Vaxart Inc
2024/01/19	22 : 30	GlobeNewswire Inc.	Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate	NASDAQ:VXRT	Vaxart Inc
2024/01/17	07 : 18	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2024/01/16	23 : 25	GlobeNewswire Inc.	Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management	NASDAQ:VXRT	Vaxart Inc
2024/01/16	23 : 22	GlobeNewswire Inc.	Vaxart, Inc. Announces Management Change	NASDAQ:VXRT	Vaxart Inc
2024/01/16	23 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2023/12/21	22 : 00	GlobeNewswire Inc.	Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	NASDAQ:VXRT	Vaxart Inc
2023/11/03	05 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VXRT	Vaxart Inc
2023/11/03	05 : 11	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VXRT	Vaxart Inc
2023/11/03	05 : 01	GlobeNewswire Inc.	Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results	NASDAQ:VXRT	Vaxart Inc
2023/11/02	21 : 00	GlobeNewswire Inc.	Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	NASDAQ:VXRT	Vaxart Inc